Neuroendocrine cancer (including neuroendocrine tumors/NET or neuroendocrine carcinoma/NEC) can feel isolating. Because the disease is uncommon and often misunderstood, many patients and caregivers spend months or years searching for clear information, experienced providers, and people who truly understand what they are facing. That is why in-person education and connection matters. The 2026 NET Cancer Day Symposium will bring the neuroendocrine cancer community together in Las Vegas, Nevada, on Sunday, November 8th, to focus on education, connection, and awareness. This is an opportunity for patients, caregivers, and advocates to interact with healthcare professionals in an intimate forum. You’ll be provided with the rare opportunity to hear directly from clinicians and specialists who understand neuroendocrine cancer and can help patients and caregivers build their knowledge, better understand the disease, learn about current therapies, and gain insight into questions they may want to discuss with their own care teams. This can help you feel more prepared and empowered to tackle your care and navigate complex decisions. The goal is not to replace conversations with your medical team. Instead, educational events can help you become a well-informed partner in those conversations. Education does not only come from the stage. It also comes from conversations in the room. The symposium is intended to create space for connection among patients, caregivers, clinicians, advocates, and supporters. Living with neuroendocrine cancer can bring uncertainty, stress, and emotional challenges. In-person gatherings can help patients and caregivers feel less alone and more connected to a community that understands the realities of neuroendocrine cancer. Hearing from others who are living with neuroendocrine cancer, caring for a loved one, or working to advance the field can offer encouragement, perspective, and a renewed sense of solidarity. “I have been part of the NET community for more than a decade, and some of my most meaningful experiences have come from sitting with the NCF team, exchanging ideas and shaping topics for meetings throughout the years—not only for NET Cancer Day. We do this because we genuinely love the work and care deeply about creating valuable experiences for the NET community. It is especially meaningful to have such an active role in planning and hosting the 2026 NET Cancer Day Symposium, and I am truly looking forward to welcoming everyone for a productive, engaging, and exciting meeting.” - Taymeyah Al-Toubah, Interim NCF Program Director RAISE AWARENESS TOGETHER NET Cancer Day is a global opportunity to increase awareness of neuroendocrine cancer. The 2026 NET Cancer Day Symposium will be part of that broader effort by bringing people together to learn, connect, and help expand understanding of this complex and often misdiagnosed disease. When patients, caregivers, advocates, clinicians, and supporters gather in person, they help enhance neuroendocrine cancer awareness within your community. JOIN US IN LAS VEGAS The 2026 NET Cancer Day Symposium will take place in Las Vegas, Nevada, from 8:30 AM to 3:00 PM, on Sunday, November 8th, at the JW Marriott Las Vegas Resort & Spa, 221 N Rampart Blvd Las Vegas, NV 89145. Whether you are newly diagnosed, have been living with neuroendocrine cancer for years, are caring for a loved one, or want to better understand this disease, the symposium is an opportunity to learn, connect, and take the next step with support. Thanks to the generosity of sponsors, we invite you to join us at no cost. Breakfast, lunch and beverages will be provided. Register for this in-person event: NCF.net/events/ncd2026 THANKS TO OUR SPONSORS

Taymeyah Al-Toubah, MPH, CCRP The Neuroendocrine Cancer Foundation ("NCF") is grateful to welcome Taymeyah Al-Toubah, MPH, CCRP, in a special support role as the Interim Program Director during the remainder of 2026. Taymeyah will support NCF’s programs and educational efforts from July 1 through December 31, 2026, helping ensure continuity for the patients, caregivers, clinicians, and community members who rely on NCF for trusted education, resources, and connection. This temporary support comes as Lisa Yen, NP, NBC-HWC, NCF’s Director of Programs & Outreach, takes time following the passing of her beloved husband, Tom Bajoras. Taymeyah brings more than a decade of experience in academic medicine, clinical research, oncology, and neuroendocrine tumor research. She holds dual bachelor’s degrees in Biomedical Sciences and Psychology and a Master of Public Health in Epidemiology. Her interest in neuroendocrine tumors began during her MPH thesis, which became one of her first NET publications. From 2018 to 2023, Taymeyah served as the primary neuroendocrine tumor (NET) coordinator at Moffitt Cancer Center, managing clinical trials, leading the GI team, and supporting retrospective and non-interventional research. She later served as Senior Project Manager of the NET program, overseeing protocol development, database creation, manuscript writing, and the curation of a master database of more than 10,000 NET patients. Taymeyah has published more than 45 manuscripts and has presented at both Europeon Neuroendocrine Tumor Society (ENETS) and the North American Neuroendocrine Tumor Soceity (NANETS). She serves on the Board of Directors of NANETS and co-founder and medical advisory committee of FLaNET Carcinoid Community, and she continues to mentor students pursuing neuroendocrine tumor research. In 2025, she began medical school in Italy, continuing her path toward becoming a physician-scientist dedicated to advancing care for neuroendocrine cancer patients. We are thankful to Taymeyah for stepping in during this meaningful time and grateful to our staff, Board, volunteers, medical advisors, and community partners for continuing to support NCF’s mission. As always, NCF remains committed to providing trusted education, support, and resources for people impacted by neuroendocrine cancer. If you have any questions, email the NCF team at info@NCF.net. THANKS TO OUR SPONSORS

Team Craig chose the Neuroendocrine Cancer Foundation (NCF) to support its work on behalf of patients and families affected by neuroendocrine cancer. Team Craig is named in honor of Craig Adams, who lost his battle with a form of neuroendocrine cancer in 2015. His sons, Ben and John Adams, promised to honor his legacy and give back to the community that helped give their family eight extra years with him. What began as a tribute to their father has grown into a powerful tradition: each year, a lacrosse team made up of friends and teammates from across the country competes in the Vail Lacrosse Shootout, united by Craig’s legacy and a shared passion for the game. Team Craig has quickly become one of the top competitors in the tournament, finishing third in 2024 and winning the tournament championship in 2025. In 2026, the team returned to compete again with a renewed mission to raise awareness and funds for families affected by neuroendocrine cancer. This year, Team Craig took that mission one step further by dedicating its efforts to supporting NCF’s work to expand awareness, education, and patient resources for those impacted by this complex and uncommon disease. The effort included a casual community gathering at Ratio Beerworks - OVERLAND in Denver, where supporters came together for live music, refreshments, conversation, and community in support of NCF. Neuroendocrine cancer can be difficult to diagnose and treat, and many patients experience years of misdiagnosis or undiagnosed symptoms. NCF works to change that by providing education and resources for patients and caregivers, increasing awareness and understanding of neuroendocrine cancers, connecting patients to experts and information about treatment options and clinical trials, and supporting a community for people navigating diagnosis and care. As Heather Davis, NCF’s Director of Community Engagement, reflected, navigating a difficult cancer can feel a lot like the unpredictable path of a loose ground ball in lacrosse. You never know exactly which way it will bounce, and the next challenge can come quickly. For many people living with neuroendocrine cancer, that uncertainty is part of daily life. There is often a constant need to adapt, make decisions, overcome obstacles, and prepare for what comes next. In lacrosse, one of the most important skills is cradling the ball: keeping it secure in the pocket of the stick while running, dodging defenders, preparing to pass, or taking a shot. That image feels especially meaningful for the neuroendocrine cancer community. Living with an uncommon cancer requires strategy, skill, focus, and agility. It requires a team that can help protect, guide, and support patients and families as they move through each stage of care. That is why NCF is so grateful to Team Craig, the Adams family, Chase Konkel, and everyone who helped bring this effort to life. Their generosity and commitment are helping NCF “cradle” the neuroendocrine cancer community by supporting those living with this uncommon cancer and helping connect more people to the resources and expertise they need. Although Team Craig did not take home the championship this year, their presence on the field represented something far greater than a final score. They played with purpose, honoring Craig’s memory and continuing a legacy rooted in teamwork, resilience, and care for others. NCF believes it takes a strong team to face cancer and to live well despite it. Team Craig is helping make that possible so that no one has to face neuroendocrine cancer alone. A special shoutout to Bodango for bringing the music and positive energy to the event and helping make the gathering even more memorable. We extend our heartfelt thanks to Ben and John Adams, Chase Konkel, the Adams family, donors, supporters, and Team Craig Lacrosse. Your commitment to this community is deeply meaningful, and your support will help NCF continue providing education, connection, and hope to patients and families affected by neuroendocrine cancer.

The Giovanna Joyce Imbesi Above & Beyond Award The Giovanna Joyce Imbesi Above & Beyond Award is given to individuals in recognition of outstanding dedication to NET patient advocacy. Recipients of this award demonstrate an attitude of excellence, awareness, and hope for the neuroendocrine cancer community. The award is in honor of the late founder of LACNETS (now Neuroendocrine Cancer Foundation), Giovanna Joyce Imbesi . 2025 Awardee DUSTY HURLEY Watch the award presentation 2024 Awardee VAL TIPPY Watch the award presentation 2023 Awardee TOM BAJORAS Watch the award presentation 2022 Awardee MICHEL DEQUEVEDO Watch the award presentation 2021 Awardee SAMUEL PRENTICE JR. Watch the award presentation 2020 Awardee MARY DONLEVY Watch the award presentaion 2019 Awardee BRENT CURRIE Watch the award presentation 2018 Awardee BETH DEBLASE Watch the award presentation

Wellness Coaching Interest Form This coaching is about wellness coaching and self-care. It does not involve navigation or NET-specific discussions. For NET-specific information and resources, visit our Resources Page . For NET support assistance, go to our Support Line .

Symptom Management < Back to Topics Play Video Play Video 01:24:02 Practical Tips in Managing Neuroendocrine Cancer Care • • Sep 29, 2026 ABOUT Join Taymeyah and Tiffany as they share important insights to help you spearhead your medical team and confidently navigate your healthcare. Gain practical logistics for managing the ongoing cycle of scans, lab work, and "ologist" appointments. Discover well-informed, real-world suggestions on finding and building strong partnerships with your providers and specialists. We hope this discussion empowers you to effectively and efficiently coordinate your care. Visit the event page at https://www.ncf.net/events/sep2026 Play Video Play Video 01:09:03 Episode 49: "Understanding Carcinoid Syndrome & GLP-1 Drugs in Neuroendocrine Tumors" - Dr. Dillon ABOUT THIS EPISODE Carcinoid syndrome can be confusing and often difficult to diagnose. In this episode, Dr. Joseph Dillon, Endocrinologist and Director of the University of Iowa Neuroendocrine Multidisciplinary Tumor Clinic, explains what carcinoid syndrome is, how it’s diagnosed, and the various ways it can be treated. He highlights key symptoms, testing, and treatment approaches—including somatostatin analogs and telotristat—and discusses how to distinguish carcinoid syndrome from other causes of diarrhea and flushing. In the second half of the episode, Dr. Dillon shares insights from his separate line of research on GLP-1 receptor agonist weight-loss drugs (such as Ozempic® and Mounjaro®) and their potential implications for neuroendocrine tumor patients. (Note: this topic is unrelated to carcinoid syndrome.) MEET DR. JOSEPH DILLON Dr. Dillon is a Professor of Medicine in the Division of Endocrinology at the University of Iowa Hospitals and Clinics. He directs the University of Iowa Neuroendocrine Multidisciplinary Tumor Clinic. This was the first and only US NET Clinic to be recognized as a Center of Excellence by the European NET Society. He is also the Director of the PheoPara Alliance Center of Excellence at University of Iowa. His clinical practice is entirely focused on the care of people with neuroendocrine tumors, both carcinoid type and paraganglioma. He has participated in clinical trials and publications related to diagnostic and therapeutic nuclear agents and drug therapies in this population. Prior to focusing on NET he made important discoveries in the field of GLP-1 which are now becoming of importance to NET patients taking popular weight loss drugs. TOP TEN QUESTIONS: 1. What is carcinoid syndrome? 2. Who is affected by carcinoid syndrome? How does someone know if they have carcinoid syndrome? 3. What are the tests for carcinoid syndrome? How is carcinoid syndrome distinguished from other causes of my symptoms? *Could the tests be negative but someone still have carcinoid syndrome? 4. Can someone have no evidence of neuroendocrine tumors and still have carcinoid syndrome? 5. For those who have carcinoid syndrome, what additional tests should they have? 6. Why should carcinoid syndrome be treated? What are the possible issues if it is not treated? 7. How is carcinoid syndrome treated? *What is on the horizon for carcinoid syndrome treatment? 8. Can carcinoid syndrome be prevented or detected early? 9. Is there anything people can do to prevent or lessen carcinoid syndrome symptoms? Are there any factors that worsen carcinoid syndrome such as age, weight or other diseases? 10. You recently published a study discussing possible risks of using certain weight loss drugs in people with neuroendocrine cancer. Could you tell us more about this study? What was the drug and what did you find? What does it mean? What do you want the NET patient community to understand about your recent findings? Visit https://www.ncf.net/podcast/49 for more information. Play Video Play Video 01:01:43 Episode 20 - Gastric NET, Gastrinomas & Zollinger-Ellison Syndrome (ZES) ABOUT THIS EPISODE Gastroenterologist and Neuroendocrinologist Dr. David C. Metz discusses important concepts in Gastric NET, Gastrinomas and Zollinger-Ellison Syndrome, including detection, treatments, associated risks and monitoring. He also lends valuable insight on ulcers, MEN and proton pump inhibitors. MEET THE SPEAKER David C. Metz, MD Professor of Medicine, Perelman School of Medicine Co-Director Emeritus, University of Pennsylvania Neuroendocrine Tumor Program After earning his MD from the University of the Witwatersrand's Medical School, Dr. Metz was a resident at both the Albert Einstein Medical Center and the Johannesburg General Hospital. He went on to complete fellowships at Georgetown University Hospital as well as the National Institutes of Health. Arriving at Penn Medicine in 1993, David Metz, MD, held a variety of leadership roles within the Department of Gastroenterology, including Co-Directorship of the Neuroendocrine Tumor Center and Penn NET Treatment Program. Dr. Metz was previously a staff fellow at the National Institutes of Health, where he performed basic research in pancreatic acinar cell secretion and clinical research in Zollinger-Ellison syndrome. While at Penn Medicine, he served as Chair of the North American Neuroendocrine Tumor Society (NANETS), as a member of the Liaison Committee for Recertification of the American Board of Internal Medicine (American Gastroenterological Association representative), and on the Food and Drug Administration Gastrointestinal Drugs Advisory Committee, among other positions. Dr. Metz's clinical interests at Penn included Zollinger-Ellison syndrome and other acid-peptic conditions, Helicobacter pylori infection, non-steroidal anti-inflammatory drug gastropathy and the diagnosis and management of patients with functional and non-functional neuroendocrine tumors of the pancreas and alimentary tract. An investigator for a series of prominent clinical trials in all of these areas, Dr. Metz has published more than 200 articles on topics of clinical interest and research. He retired in July 2021 after 28 years at Penn Medicine. In 2021 Dr. Metz received the NANETS Lifetime Achievement Award that honors an individual who, over the course of their career, has provided outstanding contributions to neuroendocrine disease management through research, clinical practice or educational initiatives, as well as exceptional leadership in NANETS and dedication to its mission. TOP 10 QUESTIONS 1. What is Gastric NET? How is it found? What are the symptoms? How does it differ from “stomach cancer” or other types of NETs? 2. How is Gastric NET treated and how is it monitored? 3. What is a Gastrinoma? How and where is it found? Are Gastrinomas and Gastric NET the same thing? 4. How is a Gastrinoma treated? 5. How is a Gastrinoma monitored? - How often do you recommend Endoscopies or Gastrin level lab testing? - Does a high Gastrin level mean someone has a Gastrinoma or are there other causes? Can you have a high Gastrin level without having a gastrinoma? 6. What is Zollinger-Ellison Syndrome? How is it found? What are the common symptoms from ZES/functioning Gastrinomas? 7. How is Zollinger-Ellison Syndrome treated? How is Zollinger-Ellison Syndrome monitored? Does ZES put you at risk for other conditions/complications? 8. What is a common Proton Pump Inhibitor dose for someone with ZES? Is there a danger in taking PPIs for a long time or in high doses? 9. I’ve been told I have an ulcer? Am I at risk for cancer? 10. What are advances for gastric nets, gastrinomas or Z-E syndrome that we should be aware of or excited about? *Bonus question: What last words of hope would you like to leave the NET community with? For more resources and the transcript of this episode, visit https://www.lacnets.org/podcast20. Play Video Play Video 17:59 5. What Matters About Symptom Management • Vineeth Sukrithan, MD • Neuroendocrine Cancer Foundation "What Matters About Symptom Management" 2025 Neuroendocrine Cancer Foundation Annual Patient Conference Vineeth Sukrithan, MD Medical Oncologist Ohio State University Play Video Play Video 01:29:43 When Hormones Interfere With Quality of Life • Dr. Jaydira Del Rivero • NCF 2026 When hormones are out of balance, the symptoms can have a significant impact on quality of life for people living with neuroendocrine cancer. In this Neuroendocrine Cancer Foundation (NCF) educational webinar, Dr. Jaydira Del Rivero, medical oncologist at the National Cancer Institute, explores how hormone excess, hormone deficiencies, and cancer treatments can affect the endocrine system—and what patients and caregivers should know. Topics covered include: • How hormone excess and hormone deficiency can affect the body • Hormone-related symptoms associated with neuroendocrine tumors • Carcinoid syndrome vs. serotonin syndrome • How immunotherapy may affect the pituitary, thyroid, adrenal glands, and pancreas • Adrenal insufficiency and cortisol deficiency • Thyroid dysfunction associated with cancer therapies • Endocrine effects of tyrosine kinase inhibitors (TKIs) and somatostatin analogs • Changes in blood glucose and insulin production • Sex hormone changes during treatment • Flushing related to carcinoid syndrome and menopause • GLP-1 agonists in the setting of neuroendocrine tumors • Symptoms and patterns patients should discuss with their healthcare team • Warning signs that may require urgent medical attention The goal of this session is to help patients and caregivers recognize symptoms earlier, understand when hormone testing may be appropriate, and have more informed conversations with their oncology and endocrinology teams. This webinar is for educational purposes only and is not a substitute for medical advice. Please contact your healthcare team with questions about your individual diagnosis, symptoms, or treatment. Learn more about the Neuroendocrine Cancer Foundation and its educational and support resources through NCF. Visit the event page at https://www.ncf.net/events/aug2026. Play Video Play Video 20:32 13. Navigating Treatment Side Effects • Jason Starr, DO • Mayo Clinic • 2026 NCF Conference In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Jason Starr, medical oncologist at Mayo Clinic in Jacksonville, Florida, presents “Navigating Treatment Side Effects.” Dr. Starr discusses how patients and care teams can balance treatment effectiveness with quality of life when using therapies for neuroendocrine cancers. He emphasizes the importance of early communication with the medical team, recognizing side effects promptly, holding medication when appropriate, using acute care resources when needed, and adjusting doses to find the right balance for each patient. This presentation reviews potential side effects and management strategies for somatostatin analogs, Lutetium-177 dotatate/Lutathera, PRRT, everolimus/Afinitor, CAPTEM, capecitabine, temozolomide, and tyrosine kinase inhibitors such as sunitinib and cabozantinib. Topics include fatigue, diarrhea, nausea, injection site pain, exocrine pancreatic insufficiency, blood sugar changes, gallbladder issues, bone marrow suppression, mouth sores, skin rash, blood pressure changes, wound healing concerns, thyroid issues, and medication interactions. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net. For more information about this conference, visit https://www.ncf.net/events/2026conference This video is for educational purposes only and is not a substitute for professional medical advice. Please consult your medical team with questions about your individual care or treatment. #NeuroendocrineCancer #NeuroendocrineTumors #NETCancer #NETs #TreatmentSideEffects #SideEffectManagement #PRRT #Lutathera #CAPTEM #Everolimus #Cabozantinib #SomatostatinAnalogs #MayoClinic #NCF #PatientConference Play Video Play Video 09:44 "Practical Tips For Patients Preparing For Chemotherapy" • Lisa Yen, NP, NBC-HWC NET caregiver Lisa Yen’s “show and tell” of tips, tricks, and items she and her husband found to be helpful when dealing with chemotherapy. Read LACNETS blogpost Practical Tips For Patients Preparing For Chemotherapy: https://www.lacnets.org/post/practical-tips-for-patients-preparing-for-chemotherapy. For more information on LACNETS, visit www.LACNETS.org. Play Video Play Video 06:36 "Practical Tips for Cabozantinib" with Lisa Yen Starting a new cancer treatment can feel overwhelming—but you don’t have to navigate it alone. In this video, Lisa Yen, Director of Programs and Outreach at the Neuroendocrine Cancer Foundation, shares practical tips and real-life insights for patients preparing to take Cabozantinib (Cabometyx). Drawing from both her professional experience and her personal journey supporting her husband with a neuroendocrine tumor, Lisa walks through what to expect, how to prepare, and how to manage common side effects. You’ll learn about: Key resources, including oncology pharmacists and free patient care kits What’s included in the Cabometyx care kit and how it can help Common side effects like nausea, diarrhea, hand-foot syndrome, and high blood pressure Tips for tracking symptoms and staying organized with a treatment journal How and when to take Cabozantinib safely The importance of communication with your healthcare team This video is designed to help reduce uncertainty and empower patients and caregivers with actionable, experience-based guidance. 💡 Whether you’re just starting Cabozantinib or supporting someone who is, these tips can help you feel more prepared and confident in your treatment journey. Disclaimer: Always consult your healthcare team with any questions or concerns about your care. This content is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Play Video Play Video 01:37:36 "The Latest in the Management of Functional Neuroendocrine Cancers • Jan, 2026 • Dr. Del Rivero Join this @NCFCancer educational patient event for an easy-to-understand overview of functional neuroendocrine tumors (NETs) with Dr. Jaydira Del Rivero, a medical oncologist and endocrinologist at the National Cancer Institute. Functional NETs can cause the body to produce too many hormones, leading to challenging symptoms such as low blood sugar (often seen in insulinoma), high blood sugar (glucagonoma), and other hormone-related issues. Dr. Del Rivero will explain what these syndromes are, how they’re diagnosed, and the latest updates in treatment. She will also discuss conditions that can occur because of NETs or their treatments. She will help patients understand why symptoms like hypoglycemia are more common in some NET types. Whether you’re a patient, caregiver, or simply want to better understand functional NETs, this webinar will offer practical, up-to-date information to help you feel more informed and empowered. Potential Topics: Functional NET, Hormone-producing, Insulinoma, Gastrinoma, VIPoma, Zollinger-Ellison syndrome (ZES), Carcinoid, Hypoglycemia, Diarrhea, Flushing ABOUT DR. JAYDIRA DEL RIVERO Medical Oncologist & Endocrinologist National Cancer Institute, National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. For more information, visit https://www.ncf.net/events/jan2026 Play Video Play Video 18:45 "The Endocrine in Neuroendocrine" • Run Yu, MD, Endocrinologist, UCLA •2024 NET Cancer Day Symposium Dr. Run Yu, Endocrinologist from UCLA, discusses "The Endocrine in Neuroendocrine" at the 2024 NET Cancer Day Symposium. Play Video Play Video 01:33:48 LACNETS • "Symptom Management" with Dr. David Metz • Oct 2023 Join LACNETS to hear Neuroendocrinologist, Dr. David Metz from University of Pennsylvania discuss symptom management. The presentation will cover carcinoid syndrome, pancreatic enzymes, bile acid secretion, and short bowel syndrome. He will explain current treatments, supplements, and diets that might be helpful to control NET-related symptoms. For more information, visit LACNETS.org. Play Video Play Video 21:13 13. Managing NET Symptoms & Treatment Side Effects (Dr. Sandy Kotiah) - 2022 LACNETS Conference Dr. Sandy Kotiah addresses the management of #NET symptoms and treatment side effects. Speaker: Sandy Kotiah, MD Medical Oncologist, Mercy Medical 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 05:17 Patient Story: NET Patient shares how she is thriving as a NET patient (LACNETS) NET Patient Cindy shares how she is thriving as a NET patient. November 7, 2020 To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 04:26 Patient Story: NET Patient shares about symptom management (LACNETS) NET Patient Brent shares about symptom management. June 20, 2020 To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 06:00 11. Patient Story about Symptom Management (Val) - 2021 LACNETS Virtual Conference NET Patient Val shares her experience with symptom management and NETs. 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 01:02:18 LACNETS - "Pain Management for NETs" Dr. Najmeh Sadoughi Dr. Najmeh Sadoughi "Multidisciplinary Approaches to Pain Management for Neuroendocrine Tumors" Najmeh Sadoughi, MD Board Certified Interventional Pain Specialist LACNETS Patient Education Seminar January 9, 2018 UCLA Los Angeles, California LACNETS is a program by Generate Possibility, a 501(c)(3) non-profit corporation. Los Angeles Carcinoid Neuroendocrine Tumor Society www.LACNETS.org Play Video Play Video 01:38:07 LACNETS Webinar: "Management of Diarrhea in NETs” with Dr. Shirley Paski Management of Diarrhea in NETs” with Dr. Shirley Paski Recorded on October 13th, 2020 Speaker: Shirley Paski, MD, IM/Gastroenterology, Cedars-Sinai Medical Center Learn more here: www.LACNETS.org Audio/Video - www.TVPlive.com Play Video Play Video 49:02 Symptom Management: Diarrhea, Hyperglycemia & Diabetes - 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: "Patient Story" (0:00 - 6:30) Brent, NET Patient "Symptom Management: Diarrhea" (6:30 - 29:05) David C. Metz, MD, Gastroenterology Penn Medicine "Symptom Management: NET-related Hyperglycemia and Diabetes" (29:05 - end of video) Run Yu, MD, PhD , Endocrinology UCLA Health For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 17:19 12. Symptom Management (Dr. Del Rivero) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Jaydira Del Rivero, MD Endocrinologist, Oncologist NIH This presentation is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 45:02 "Manejo Sintomatico de los Tumores Neuroedocrinos Funcionales" con Dr. Jaydira Del Rivero "Manejo Sintomatico de los Tumores Neuroedocrinos Funcionales" con Dr. Jaydira Del Rivero Presentadora: Jaydira Del Rivero, MD Endocrinologist, Oncologist; NIH Para obtener más recursos en español, visite www.LACNETS.org/spanish-resources. < Back to Topics Next Topic >